Mulakan
ReutersReuters

BridgeBio Pharma Says Acoramidis Reduces CVM Or CVH Risk By 49% Through Month 30

RefinitivBacaan kurang dari 1 minit
BBIO

BridgeBio Pharma Inc BBIO:

  • ACORAMIDIS BEGINS TO REDUCE CUMULATIVE CARDIOVASCULAR OUTCOMES WITHIN THE FIRST MONTH OF TREATMENT IN PATIENTS WITH ATTR-CM

  • BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES CVM OR CVH RISK BY 49% THROUGH MONTH 30

ReutersSaham AS
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini

Lebih berita dari Reuters